CELLSAFE
30.9.2020 06:46:11 CEST | Business Wire | Press release
CellSafe, a specialist in developing diagnostics located at the Republic of Korea and Dynasty Castle Investments Limited, a Hong Kong based company specializing in the procurement, distribution and delivery of medical supplies, today announced that they have signed an exclusive distribution agreement for Portugal and 6 African countries for the sale and distribution of LAMPlexTM RT-qLAMP COVID-19 Detection Assay, real-time reverse transcription loop-mediated isothermal amplification (LAMP) technology-based kit which can detect the novel corona virus within 25 minutes.
DCI has the rights to supply this clinically proven, reliable FAST molecular diagnostic kit in such countries in partnership with its local distributors. As this global pandemic is raging across the world, CellSafe has cooperated with Armed Forces Medical Research Institute, Republic of Korea to develop and launch LAMPlexTM RT-qLAMP COVID-19 Detection Assay.
“This unprecedented pandemic is affecting our lives everywhere. So we felt the urgency of developing LAMP detection kit which is very fast and with similar sensitivity and specificity like RT-PCR kits. We believe our LAMP kit will play crucial roles in preventing the spread of corona virus, in particular, at airports, ports, stadiums where fast detection of corona virus is required,” said Jae Jin HAN, CEO of CellSafe.
“We are very pleased to work with CellSafe to launch this FAST LAMP COVID-19 Detection Kit and are happy about the sensitivity and specificity of their kit. We are looking forward to expanding our partnership further,” commented DCI Chief Medical Officer, Dr. Rav Naik.
About LAMPlexTM RT-qLAMP COVID-19 Detection Assay
LAMPlexTM RT-qLAMP COVID-19 Detection Assay is an in vitro diagnostic medical device for the FAST detection of novel coronavirus 2019-nCoV. This device detects the virus through real-time reverse transcription loop-mediated isothermal amplification with RNA isolated from the samples (human nasopharyngeal & oropharyngeal swabs and sputum) collected from suspected SARS-CoV-2 patients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929006179/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meraki Capital Launches Tessero Across Six European Markets Following Landmark Hays Acquisition1.9.2026 22:36:00 CEST | Press release
Meraki Capital has launched Tessero,a new European specialist recruitment group created from the six former Hays plc businesses it acquired earlier this summer. Launching simultaneously across Sweden, Denmark, Hungary, Romania, Luxembourg and Czechia, Tessero brings six established recruitment businesses together under one independent European brand, creating an international platform with experienced teams, existing clients and active candidate networks from day one. The launch follows one of the most significant transactions in Meraki Capital’s history and the completion of a major transition programme across all six countries within weeks of the acquisition. 130 employees will now operate under the Tessero brand, with established country leadership teams remaining in place and continuing to lead their respective markets. Gary Elden OBE, CEO of Meraki Capital and Director of Tessero, said: “Tessero launches with something that normally takes years to build: established businesses, ex
SBC Medical to Participate in Several Upcoming Investor Conferences in September 20261.9.2026 19:35:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced its participation in several upcoming investor conferences in September 2026. SBC Medical will conduct presentations and one-on-one meetings with institutional investors. Below is a summary of the Company’s scheduled participation in upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment Conference Date: September 14 2026 Format: In-person (NY) Registration: https://my.ct.events/register.aspx?meid=cff43623-9e9f-45d4-bbc3-ee19e9c372c1&rpid=a667ca45-171e-4306-98eb-c466e8b7e6c1 ArcStone Kingswood Growth Summit 2026 Date: September 16 2026 Format: In-person (Toronto) Registration:https://www.meetmax.com/sched/event_144037/investor_reg_new.html?attendee_role_id=ARCSTONE_ATTENDEE CLSA 33rd Investors’ Forum 2026 Date: September 21, 2026 Format: In-person (Hong K
Crimson Moon Available Now, Bringing Heavy-Metal Gothic Action to Solo and Co-op Players on PC, PlayStation 5, and Xbox Series X|S1.9.2026 19:00:00 CEST | Press release
ProbablyMonsters’ action-adventure RPG offers blood-soaked combat, monstrous showdowns, and deep replay value for $19.99 USD ProbablyMonsters, an independent video game company creating original AA games with AAA sensibilities, today launched Crimson Moon on PC via Steam and Epic Game Store, PlayStation 5, and Xbox Series X|S for $19.99 USD. A $29.99 USD Deluxe Edition is also available and includes an exclusive armor set, weapon cosmetic, and upcoming game expansion. Watch the official Crimson Moon launch trailer on YouTube to see the game’s gothic heavy-metal power fantasy, crafted for both solo and co-op players, in action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901064893/en/ Crimson Moon is a gothic high renaissance action-adventure RPG built around intense, replayable missions that blend brutal precision with deep character progression. Players take on the role of the Nephilim, powerful human-angel hybrids bo
Rigaku Launches CT Lab HR160 High-Resolution X-ray CT System1.9.2026 17:00:00 CEST | Press release
- Developed in collaboration with Excillum for battery, semiconductor devices, and advanced materials analysis - Rigaku Corporation, a global solutions partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (Headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), today announced the launch of the CT Lab HR160, a high-resolution X-ray computed tomography (CT) system for battery, semiconductor devices, electronic components, and advanced materials analysis. The system is developed in collaboration with Excillum AB, the global source for X-ray innovation (Headquarters: Stockholm, Sweden; CEO: David Lindblom; “Excillum”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901074099/en/ Photo: CT Lab HR160 High-Resolution X-ray CT System CT Lab HR160 combines Rigaku’s X-ray CT imaging expertise with Excillum’s NanoTube N3 X-ray source. Operating at up to 160 kV to support a wide r
GigaDevice Joins the Zephyr® Project to Foster Global Open-Source Ecosystem1.9.2026 16:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially joined the Zephyr® Project, one of the world’s leading open-source real-time operating systems (RTOS). Hosted by the Linux Foundation®, the Zephyr® Project welcomes GigaDevice as a Silver Member, making GigaDevice a dual Silver Member of both the Zephyr® Project and the Linux Foundation. Leveraging its comprehensive GD32 MCU portfolio, GigaDevice will actively participate in the Zephyr® community, promoting deeper integration between its MCU technologies and the global open-source RTOS ecosystem. This will provide customers and developers in industrial, IoT, consumer electronics, and other fields with a more open, standardized, and efficient embedded development environment, while continuing to contribute to the growth of the global embedded open ecosystem and broader access to technology. With the continued evolution of the Internet of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom